Prospective study of liver transplant recipients with HCV infection: Evidence for a causal relationship between HCV and insulin resistance

Liver Transplantation

Volumn 14, Issue 2, 2008, Pages 193-201

  Delgado Borrego, Aymin ^a,b,c   Liu, Yun Sheen ^a   Jordan, Sergio H ^a   Agrawal, Saurabh ^a   Zhang, Hui ^a   Christoff, Marielle ^c   Casson, Deborah ^a   Cosimi, A Benedict ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISONE; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADULT; AGED; ANTIVIRAL AGENTS; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 39449099338     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21267     Document Type: Article

References (31)

1. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994;21:1135-1139.
2. Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004;77:703-710.
3. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003;125:1695-1704.
4. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol 2001;88:16H-19H.
5. McLaughlin TL, Reaven GM. Beyond type 2 diabetes: the need for a clinically useful way to identify insulin resistance. Am J Med 2003;114:501-502.
6. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall'Aglio E, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes melitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999;48:989-994.
7. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002;25:1135-1141.
8. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000;160:1160-1168.
9. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
10. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39:1042-1048.
11. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744.
12. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, et al. Insulin and insulin-like growth factor- 1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999;29: 1743-1751.
13. Patel K, Muir A, McHutchison JG, Patton HM. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. Am J Gastroenterol 2003;98:952-955.
14. Garg A, Misra A. Hepatic steatosis, insulin resistance, and adipose tissue disorders. J Clin Endocrinol Metab 2002; 87:3019-3022.
15. Heathcote J. Weighty issues in hepatitis C. Gut 2002; 51: 7-8.
16. Monto A. Hepatitis C and steatosis. Semin Gastrointest Dis 2002;13:40-46.
17. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002;37:837-842.
18. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36:729-736.
19. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
20. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-597.
21. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
22. Skinner HA, Sheu. WJ. Reliability of alcohol use indices. The lifetime drinking history and the MAST. J Stud Alcohol 1982;43:1157-1170.
23. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-1735.
24. Baid S, Cosimi AB, Farrell ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001;72:1066-1072.
25. Rostaing L, Izopet J, Sandres K, Cisterne JM, Puel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000;69:991-994.
26. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf WJ, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001;7: 1064-1070.
27. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
28. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
30. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
31. Saliba F, Lakehal M, Pageaux GP, Roche B, Vanlemmens C, Duvoux C, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis c infection: An observational multicenter study. Liver Transpl 2007;13:136-144.